Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 3,591 matching trials from the live ClinicalTrials.gov search.
Conditions
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
Interventions
Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy
Device · Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Thoracic Diseases, Respiratory Tract Diseases, Cancer of Lung, Cancer of the Lung, Lung Cancer, Lung Diseases, Obstructive, COPD, Pulmonary Emphysema, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell
Interventions
Skin Biopsy
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma, Metastatic Melanoma, Locally Advanced Renal Cell Carcinoma, Metastatic Clear-Cell Renal Cell Carcinoma
Interventions
Retifanlimab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Fresno, California • San Marcos, California • Santa Rosa, California + 13 more
Conditions
Adenocarcinoma, Non-Small-Cell Lung Carcinoma, Lung Neoplasms
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Fountain Valley, California • Los Angeles, California • Palm Springs, California + 8 more
Conditions
Non-Small Cell Lung Cancer, Adenocarcinoma
Interventions
SS1 (dsFv) PE38, Paclitaxel, Carboplatin, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
NBF-006
Drug
Lead sponsor
Nitto BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
9
States / cities
Beverly Hills, California • La Jolla, California • Tampa, Florida + 6 more
Conditions
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions
A2B530, xT-Onco with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more
Conditions
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee
Conditions
Lung Cancer (NSCLC)
Interventions
JBI-802, Pembrolizumab
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
placebo, BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
14
States / cities
Kingman, Arizona • Fayetteville, Arkansas • Anaheim, California + 11 more
Conditions
Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma
Interventions
Afatinib, Regorafenib, Cabozantinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 5 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed and Gemcitabine plus Bevacizumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
Waterbury, Connecticut • Augusta, Georgia • Macon, Georgia + 7 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
19
States / cities
Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions
DJI136
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Lexington, Kentucky • Houston, Texas • Seattle, Washington
Conditions
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer
Interventions
Cirtuvivint, Irinotecan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Dacomitinib, Doxycycline, Probiotic, Alclometasone cream
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
79
States / cities
Duarte, California • Fullerton, California • Irvine, California + 49 more
Conditions
Lung Cancer, Non-Small Cell
Interventions
pazopanib, paclitaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Columbus, Ohio
Conditions
Non Small Cell Lung Cancer
Interventions
Lobectomy
Procedure
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
28
States / cities
Duarte, California • Aurora, Colorado • Lone Tree, Colorado + 24 more
Conditions
Lung Cancer
Interventions
DNA analysis, DNA methylation analysis, RNA analysis, gene expression analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
11
States / cities
Los Angeles, California • Lewes, Delaware • Newark, Delaware + 7 more
Conditions
Stage IIIA Non-small Cell Lung Cancer
Interventions
proton beam radiation therapy, cisplatin, etoposide, therapeutic conventional surgery
Radiation · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Springdale, Arkansas • New Haven, Connecticut • Jacksonville, Florida + 6 more
Conditions
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
Interventions
NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2043
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 14 more